Elderly patients are underrepresented in clinical trials for ischemic heart disease drugs, highlighting a gap between trial populations and real-world disease burden.
Results of ischemic heart disease drug trials may not apply to older adults; challenges generalizability of current evidence to highest-prevalence age groups.
Despite the high burden of IHD in elderly adults, the majority of drug trials do not enroll participants reflective of age-related prevalence of the disease.
No takes yet. Share an insight, caveat, or question.
Bourgeois et al. (2017) studied this question.